Literature DB >> 25877395

What Is Next for Retinal Gene Therapy?

Luk H Vandenberghe1.   

Abstract

The field of gene therapy for retinal blinding disorders is experiencing incredible momentum, justified by hopeful results in early stage clinical trials for inherited retinal degenerations. The premise of the use of the gene as a drug has come a long way, and may have found its niche in the treatment of retinal disease. Indeed, with only limited treatment options available for retinal indications, gene therapy has been proven feasible, safe, and effective and may lead to durable effects following a single injection. Here, we aim at putting into context the promise and potential, the technical, clinical, and economic boundaries limiting its application and development, and speculate on a future in which gene therapy is an integral component of ophthalmic clinical care.
Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25877395      PMCID: PMC4588134          DOI: 10.1101/cshperspect.a017442

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  39 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.

Authors:  C-M Lai; M J Estcourt; R P Himbeck; S-Y Lee; I Yew-San Yeo; C Luu; B K Loh; M W Lee; A Barathi; J Villano; C-L Ang; R G van der Most; I J Constable; D Dismuke; R J Samulski; M A Degli-Esposti; E P Rakoczy
Journal:  Gene Ther       Date:  2011-11-10       Impact factor: 5.250

3.  Reply to Townes-Anderson: RPE65 gene therapy does not alter the natural history of retinal degeneration.

Authors:  Artur V Cideciyan; Samuel G Jacobson; William A Beltran; William W Hauswirth; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-07       Impact factor: 11.205

4.  Mutations in RPE65 cause Leber's congenital amaurosis.

Authors:  F Marlhens; C Bareil; J M Griffoin; E Zrenner; P Amalric; C Eliaou; S Y Liu; E Harris; T M Redmond; B Arnaud; M Claustres; C P Hamel
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

5.  Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012.

Authors:  Marina O'Reilly; Donald B Kohn; Jeffrey Bartlett; Janet Benson; Philip J Brooks; Barry J Byrne; Carlos Camozzi; Kenneth Cornetta; Ronald G Crystal; Yuman Fong; Linda Gargiulo; Rashmi Gopal-Srivastava; Katherine A High; Samuel G Jacobson; Robert C Jambou; Maureen Montgomery; Eugene Rosenthal; R Jude Samulski; Sonia I Skarlatos; Brian Sorrentino; James M Wilson; Yun Xie; Jacqueline Corrigan-Curay
Journal:  Hum Gene Ther       Date:  2013-04       Impact factor: 5.695

Review 6.  Retinal degeneration mutants in the mouse.

Authors:  B Chang; N L Hawes; R E Hurd; M T Davisson; S Nusinowitz; J R Heckenlively
Journal:  Vision Res       Date:  2002-02       Impact factor: 1.886

7.  Adenovirus vector-mediated in vivo gene transfer into adult murine retina.

Authors:  J Bennett; J Wilson; D Sun; B Forbes; A Maguire
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-04       Impact factor: 4.799

8.  In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Authors:  Deniz Dalkara; Leah C Byrne; Ryan R Klimczak; Meike Visel; Lu Yin; William H Merigan; John G Flannery; David V Schaffer
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

9.  Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo.

Authors:  Tanya Tolmachova; Oleg E Tolmachov; Alun R Barnard; Samantha R de Silva; Daniel M Lipinski; Nathan J Walker; Robert E Maclaren; Miguel C Seabra
Journal:  J Mol Med (Berl)       Date:  2013-06-12       Impact factor: 4.599

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  6 in total

Review 1.  CRISPR applications in ophthalmologic genome surgery.

Authors:  Thiago Cabral; James E DiCarlo; Sally Justus; Jesse D Sengillo; Yu Xu; Stephen H Tsang
Journal:  Curr Opin Ophthalmol       Date:  2017-05       Impact factor: 3.761

Review 2.  Nonhuman Primate Studies to Advance Vision Science and Prevent Blindness.

Authors:  Michael J Mustari
Journal:  ILAR J       Date:  2017-12-01

Review 3.  CRISPR-Cas Genome Surgery in Ophthalmology.

Authors:  James E DiCarlo; Jesse D Sengillo; Sally Justus; Thiago Cabral; Stephen H Tsang; Vinit B Mahajan
Journal:  Transl Vis Sci Technol       Date:  2017-05-31       Impact factor: 3.283

Review 4.  Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy.

Authors:  Sara E Ratican; Andrew Osborne; Keith R Martin
Journal:  Neural Plast       Date:  2018-05-02       Impact factor: 3.599

5.  The epigenetic basis for the impaired ability of adult murine retinal pigment epithelium cells to regenerate retinal tissue.

Authors:  Galina Dvoriantchikova; Rajeev J Seemungal; Dmitry Ivanov
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

6.  Notch Signaling-Induced Oscillatory Gene Expression May Drive Neurogenesis in the Developing Retina.

Authors:  Dmitry Ivanov
Journal:  Front Mol Neurosci       Date:  2019-09-19       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.